Navigation Links
Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
Date:6/16/2010

s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='96457079';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.abbott.com/">www.abbott.com

Neurocrine Biosciences Forward Looking Statement

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include, but are not limited to, risk that the elagolix clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to Phase III clinical trials; risk associated with the Company's dependence on Abbott for Phase III development, commercial manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31,
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
2. Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramals Healthcare Solutions Business
3. Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
4. Updated Abbott Statement: To Help Respond to Growing Health Crisis, Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts
5. Abbott Hosts Conference Call for Third-Quarter Earnings
6. Abbott Declares 343rd Consecutive Quarterly Dividend
7. Abbott Wins Top Honor in Wall Street Journal Technology Innovation Awards
8. Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
9. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
10. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
11. Abbott HIV Test Demonstrates Earlier Disease Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Decision Resources Group finds that the Latin ... percent compound annual growth rate through 2023. This is ... the increasing adoption of dental implants. Growing aesthetic consciousness ... spur demand for dental biomaterials because they can improve ... Other key findings from Decision Resources Group,s ...
(Date:12/19/2014)... December 18, 2014 BioPlus ... leading specialty pharmacies, has an expanded team of ... pharmacy consultants for prescriber offices in their regions, ... , “We have a variety of Regional Pharmaceutical ... those specializing in hepatitis C help prescribers understand ...
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... Reports from CDC show ... from one or more chronic health conditions - including ... address some of these diseases, but may not eliminate ... face. While implanted nerve stimulation devices today offer relief, ... which can induce side effects. , To eliminate ...
Breaking Biology Technology:Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... Symbol: MS, EDMONTON, May 5 /PRNewswire-FirstCall/ - BioMS ... of multiple sclerosis (MS), will hold,its Annual General Meeting ... 4:00,p.m. (ET)., A live audio webcast of the ... connect at least ten minutes prior to the,conference call ...
... Cequent Pharmaceuticals, a,pioneer in the development of ... and treat human disease, announced that Michael ... of directors. Dr. Taylor is,president and chief ... Massachusetts-based biotechnology company developing novel,classes of therapeutics ...
... Wednesday, May 7th at 9:30am EDT, NEW YORK, ... today announced that Michael S. Weiss, the Company,s,Chairman and ... Bank 33rd Annual Health Care Conference in Boston, Massachusetts., ... Wednesday, May 7th at,9:30am EDT, will be webcast live ...
Cached Biology Technology:BioMS Medical announces conference call and web cast for Annual General Meeting 2Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals' Board of Directors 2Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference 2
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   ... platform built for the post-password and Internet of Things ... additional seed funding. The venture round was led by ... Pantera Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey ... the new funding to expand its team and bring ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense ... it easier to detect and prevent counterfeit microcircuits ... Today the agency started performing an in-house microcircuit ... validate the authenticity of purchased microcircuits while increasing ... quality control measures will be conducted at DLA,s ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... mysteries of modern coral reefs is how they evolved from ... in the record of coral evolution. This evolutionary gap ... and changes in the Earth,s climate between 1 and 2 ... went extinct, and the modern reef corals emerged. To ...
... Bioinformatics Laboratory at the University of Illinois in collaboration ... probe the world of proteins for answers to questions ... formed from chains of amino acids and fold into ... sciences professor Gustavo Caetano-Anolls, very little is known about ...
... a new study carried out at the Norwegian Institute of ... supplements from four weeks before conception to eight weeks into ... birth to children with childhood autism (classic autism). "It ... before conception to eight weeks into pregnancy," states Pl Surn, ...
Cached Biology News:University of Miami geologists to address the mystery of an evolution gap in reef corals 2Untangling life's origins 2Untangling life's origins 3Folic acid lowers risk of autism 2
Polio component type I...
... 'A New Concept in Microarrays: Biomedical ... chip technologies GmbH (Jena, Germany) have collaborated ... new CLONDIAG ArrayTube System. The DNAscope ... technology. The new DNAscope AT automatically reads ...
... AccuSpot automates LC micro-fractionation, spotting and ... AccuSpot system, LC eluent can be ... plates, in trace amounts. This allows ... for MALDI-TOF-MS measurements. When used in ...
... PF 2D is an automated, two-dimensional fractionation ... mixtures. Part of Beckman Coulters ProteomeLab ... results in just hours. The system ... in cell lysates, addressing a key challenge ...
Biology Products: